Citizens Rates Crinetics Pharmaceuticals (CRNX) buy

Citizens reaffirms its positive outlook on Crinetics Pharmaceuticals, setting a target price significantly above the current trading level, a 170.50% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 17, 2026, 5:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citizens rated Crinetics Pharmaceuticals, Inc. ($CRNX) "buy" with a $95 price target on June 11, 2026.

Since the rating, $CRNX is up 7.0% after 1 week and up 5.5% to date (from the $33.53 close on Jun 11, 2026).

CRNX Crinetics Pharmaceuticals, Inc.

$35.38 -24.29% year to date

Daily close · Jun 22, 2026

Key Points

Citizens reiterated its buy rating on Crinetics Pharmaceuticals (CRNX) with a target price of $95.00, while the stock is currently trading at $35.12.
Citizens's $95 price target implies 170.50% upside from Crinetics Pharmaceuticals, Inc.'s ($CRNX) current $35.12 share price.
The company had a revenue of $42.2 million in its latest financial reporting, showing a revenue growth rate of 23.4%.
Crinetics Pharmaceuticals has no current dividend, focusing instead on its innovative therapeutics within the biotechnology sector.

Get $CRNX trade alerts by text

We text you when insiders, Congress or big funds trade $CRNX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Crinetics Pharmaceuticals, Inc. alert may contain errors. Disclosures

Citizens Stands Firm on Crinetics' Outlook

On June 11, 2026, Citizens reiterated its buy rating on Crinetics Pharmaceuticals, Inc. (CRNX) with a target price of $95.00. Currently, the stock trades at $35.12, suggesting a substantial gap to the target price, which highlights the firm’s confidence in the company's future potential.

Understanding the Rating

This reaffirmation by Citizens comes as the stock has shown volatility, trading well below its 52-week high of $85.01. The buy rating reflects the analyst's belief in Crinetics’ prospects, especially given the company's focus on developing treatments for rare endocrine diseases. The strong revenue growth of 23.4% reported recently adds to the bullish sentiment around the stock.

Analysts Set New Price Targets

The broader analyst sentiment surrounding Crinetics has shifted recently, with several firms downgrading their ratings. UBS downgraded the stock to Neutral on July 28, 2026, adjusting its target down to $85.00 from $55.00. Similarly, TD Cowen, Evercore ISI Group, Jones Trading, Jefferies, and Oppenheimer have all made moves to downgrade their ratings to Hold or Neutral, often citing a target of $85.00. These changes reflect a cautious approach as the market assesses Crinetics’ operational performance against its lofty targets.

Stock Performance Context

As Crinetics Pharmaceuticals navigates through these market dynamics, its current trading price at $35.12 is significantly below the average price targets set by various analysts, suggesting a potential opportunity for investors looking for undervalued stocks in the biotechnology sector. The stock remains positioned well for growth, especially as it continues to advance its clinical trials and product development.

12-month forecast

$CRNX price target

Crinetics Pharmaceuticals, Inc. daily closes and this analyst's $95 target. Not advice.

What Crinetics Pharmaceuticals, Inc. Does

Crinetics Pharmaceuticals, based in San Diego, California, specializes in discovering and developing novel therapeutics for rare endocrine diseases and tumors. The company’s lead candidate, Paltusotine, is currently in Phase 3 trials, targeting conditions like acromegaly and carcinoid syndrome. This innovative approach is critical to their strategy as they aim to carve out a niche in the competitive biotechnology landscape.

What to Watch at Crinetics Pharmaceuticals, Inc.

Investors will be keenly observing further developments from Crinetics, particularly the upcoming earnings report scheduled for November 5, 2026. The firm's next steps in its clinical trials and any updates from analysts will also be pivotal in assessing its performance moving forward. Remember, the information in the analyst reports, including Citizens' reiteration, reflects past performance and expectations as of the filing date and may not represent current market conditions.